ICUS is urging the US Food and Drug Administration (FDA) to approve a whole-body indication for ultrasound contrast agents.
- ICUS submitted a written statement on June 9, 2026, in response to the FDA’s request for input on repurposing approved drugs for new uses. READ MORE
- ICUS also presented to Reagan-Udall Foundation for the FDA on August 5, 2026. The ICUS presentation was entitled “A safe, affordable way to improve care: Repurpose approved UCAs for whole-body use.” READ MORE
ICUS believes that imaging drugs, as well as therapeutic drugs, are ripe for repurposing because they are safe, affordable options that impact patient care and outcomes and have significant potential for broader uses.
Although FDA-approved adult indications are currently limited to the heart and liver, professional guidelines and clinical experiences demonstrate benefits across a wider range of clinical settings.
The safety of ultrasound contrast agents has been established in clinical trials to the satisfaction of the FDA, as well as in a large body of scientific publications.
Moreover, a single intravenous injection of an ultrasound contrast agent will show perfusion of organs throughout the body and the choice of organ does not alter patient risk. By simply moving an external ultrasound transducer, a clinician can evaluate pathology across organ systems, following disease wherever it may be found.